REG - Oncimmune Hldngs PLC - Director/PDMR's Dealing

Oncimmune HoldingsAnnouncement

02/03/2020 15:40

RNS Number : 7386E
  
Oncimmune Holdings PLC
  
02 March 2020
  
 

Oncimmune Holdings plc
 
("Oncimmune" or the "Company")
 
Director/PDMR's Dealing
 
Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, announces the following dealing in the Company's ordinary shares of £0.01 each in the Company ("Ordinary Shares") by Carsten Schroeder, PDMR and Non-Executive Director. The Company was notified on 28 February 2020.
 



PDMR


Date of purchase


Number of shares purchased


Purchase price


Total shares held


% ISC held following

purchase




Carsten Schroeder


28 February 2020


9,000


£0.541


9,000


0.00014%



 
This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the EU Market Abuse Regulation.
 
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
 



1
 


Details of the person discharging managerial responsibilities / person closely associated
 




a)
 


Name
 
 


Carsten Schroeder




2
 


Reason for the notification
 




a)
 


Position/status
 
 


Non-Executive Director




b)
 


Initial notification /Amendment
 
 


Initial notification




3
 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 




a)
 


Name
 
 


Oncimmune Holdings plc




b)
 


LEI
 
 


213800HCYIWT6YPI1I02 




4
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
 
 




a)
 


Description of the financial instrument, type of instrument


Ordinary Shares of £0.01 each
 














Identification code


ISIN: GB00BYQ94H38














b)
 


Nature of the transaction
 
 


Purchase of shares




c)
 


Price(s) and volume(s)




























Price


Volume
















0.541 GBP


9,000 






























d)
 


Aggregated information


















- Aggregated volume


Same as above














- Price


















e)
 


Date of the transaction
 
 


28 February 2020




f)
 


Place of the transaction
 
 


London stock exchange, AIM



 
For further information:
 
Oncimmune Holdings plc
Andrew Stewart, General Counsel and Company Secretary
contact@oncimmune.com 
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
DSHSSDFIEESSEDD